Reportedly, the final outcomes are in for MOMENTUM 3, which is the LVAD (largest left-ventricular assist device) test ever conducted. The study of over 1,000 patients having severe heart failure confirms that the HeartMate 3—which is a latest-generation LVAD device—noticeably lowered the need for re-operations owing to pump malfunctions. The study also found that it reduced jeopardy of strokes and bleeding events, correlated to the HeartMate II. The outcomes were presented at the ACC’s (American College of Cardiology) 68th Annual Scientific Session.
Mandeep Mehra—Medical Director of the Heart & Vascular Center at Brigham and Women’s Hospital—stated, “We are excited to have finished the biggest LVAD test in the world, to make out that all of the untimely benefits we monitor in interim analyses were continued, and to report lessening in pump-related thrombosis, mucosal bleeding, and strokes—which are 3 measures of hemocompatibility—in comparison to the past generation of cardiac pump.” Mehra further added, “Our outcomes must encourage confidence that we now have an advanced pump and should give reassurance to doctors that we do not require to wait till a patient is “near death” to think this option for our patients.” The study was published in the New England Journal of Medicine.
Similarly, Brigham and Women’s Hospital was in news for developing a blood test to forecast spontaneous preterm birth. Pregnancy could be a time of hesitation for expecting ladies and their medical care teams. Almost 10% of births are premature, which takes place prior to 37 Weeks gestation. Preterm birth can outcome from many conditions, counting preterm burst of the placental membrane, preterm labor, or preeclampsia. Scientists from Brigham and Women’s Hospital were developing a blood test to aid in predicting who might be at greater, lower, or average risk for spontaneous preterm delivery. The study was published in the American Journal of Obstetrics & Gynecology.